That was better than expected. Analysts had expected $13.8 billion on average, according to Bloomberg.
Adjusted profit fell 18 percent to $4.3 billion, down from $5.2 billion a year earlier.
Pfizer's stock rose 2 percent in futures trading after the report, ahead of Tuesday's trading on Wall Street.
For the full year, Pfizer confirms its forecast of $59.5 billion to $62.5 billion in revenue, which compares to an average forecast of $61.4 billion.
"We have gotten 2026 off to a strong start," says Chairman and CEO Albert Bourla in a press release.
